{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:18:37Z","timestamp":1792819117971,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0074-7","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T09:49:17Z","timestamp":1370425757000},"page":"989-997","source":"Crossref","is-referenced-by-count":86,"title":["Metreleptin: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Ken","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,6]]},"reference":[{"issue":"2","key":"74_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","volume":"16","author":"EA Oral","year":"2010","unstructured":"Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract. 2010;16(2):324\u201333.","journal-title":"Endocr Pract."},{"issue":"6","key":"74_CR2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","volume":"17","author":"JL Chan","year":"2011","unstructured":"Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922\u201332.","journal-title":"Endocr Pract."},{"issue":"2","key":"74_CR3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","volume":"16","author":"JL Chan","year":"2010","unstructured":"Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010;16(2):310\u201323.","journal-title":"Endocr Pract."},{"issue":"3","key":"74_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","volume":"7","author":"CG Fiorenza","year":"2011","unstructured":"Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7(3):137\u201350.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"74_CR5","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-24716-3_1","volume-title":"Appetite Control","author":"EC Cottrell","year":"2012","unstructured":"Cottrell EC, Mercer JG. Leptin receptors. In: Joost HG, editor. Appetite Control. New York: Springer; 2012. p. 3\u201321."},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570\u20138.","journal-title":"N Engl J Med"},{"key":"74_CR8","unstructured":"Shionogi Co Ltd. Shionogi Filed a New Drug Application for Recombinant Human Leptin for Lipodystrophy [media release]. 01 Aug 2012. http:\/\/www.shionogi.co.jp\/ir_en\/news\/detail\/e_120801.pdf . Accessed 22 May 2013."},{"key":"74_CR9","unstructured":"Shionogi Co Ltd. Shionogi Receives Marketing and Manufacturing Approval of a Drug for Lipodystrophy, \u201cMETRELEPTIN for Subcutaneous Injection 11.25 mg SHIONOGI\u201d [media release]. 25 Mar 2013. http:\/\/www.shionogi.co.jp\/ir_en\/news\/detail\/e_130325.pdf . Accessed 22 May 2013."},{"issue":"3","key":"74_CR10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jc.2011-2229","volume":"97","author":"V Simha","year":"2012","unstructured":"Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785\u201392.","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl. 1","key":"74_CR11","first-page":"12","volume":"54","author":"ED Javor","year":"2005","unstructured":"Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54(Suppl. 1):12.","journal-title":"Diabetes"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","volume":"92","author":"K Ebihara","year":"2007","unstructured":"Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92:532\u201341.","journal-title":"J Clin Endocrinol Metab."},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1542\/peds.2006-3165","volume":"120","author":"J Beltrand","year":"2007","unstructured":"Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics. 2007;120:e291\u20136.","journal-title":"Pediatrics"},{"key":"74_CR14","unstructured":"Amylin Pharmaceuticals Inc. Amylin completes biologics license application for metreleptin to treat diabetes and\/or hypertriglyceridemia in patients with rare forms of lipodystrophy [media release]. 03 Apr 2012. http:\/\/www.amylin.com . Accessed 22 May 2013."},{"key":"74_CR15","unstructured":"Amylin Pharmaceuticals Inc. amylin outlines corporate strategy to maximize global value of diabetes franchise and advance key pipeline candidates [media release]. 09 Jun 2012. http:\/\/www.amylin.com . Accessed 22 May 2013."},{"key":"74_CR16","unstructured":"Amylin Pharmaceuticals Inc. Amylin submits clinical and nonclinical sections of rolling biologics license application for metreleptin to treat rare forms of lipodystrophy [media release]. 20 Dec 2010. http:\/\/www.amylin.com . Accessed 22 May 2013."},{"key":"74_CR17","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation. Metreleptin for the treatment of Lawrence syndrome. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2012\/08\/WC500131631.pdf . Accessed 2013."},{"key":"74_CR18","unstructured":"Bristol-Myers Squibb C. Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc [media release]. 09 Aug 2012. http:\/\/www.bms.com . Accessed 22 May 2013."},{"issue":"2","key":"74_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4158\/EP.16.2.162","volume":"16","author":"CS Mantzoros","year":"2010","unstructured":"Mantzoros CS. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? Endocr Pract. 2010;16(2):162\u20136.","journal-title":"Endocr Pract."},{"issue":"9","key":"74_CR20","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jc.2003-031868","volume":"89","author":"J McDuffie","year":"2004","unstructured":"McDuffie J, Riggs P, Calis K, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrin Metab. 2004;89(9):4258\u201363.","journal-title":"J Clin Endocrin Metab."},{"key":"74_CR21","first-page":"S79","volume":"55","author":"C Vatier","year":"2012","unstructured":"Vatier C, Fetita S, Boudou P, et al. Metreleptin therapy in leptin-deficient patients with lipodystrophic syndromes: effects on insulin secretion. Diabetologia. 2012;55:S79\u201380.","journal-title":"Diabetologia."},{"issue":"1","key":"74_CR22","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1152\/ajpendo.00146.2011","volume":"301","author":"M Brinkoetter","year":"2011","unstructured":"Brinkoetter M, Magkos F, Vamvini M, et al. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. Am J Physiol Endocrinol Metab. 2011;301(1):E99\u2013104.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"74_CR23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.metabol.2011.05.016","volume":"60","author":"E Sienkiewicz","year":"2011","unstructured":"Sienkiewicz E, Magkos F, Aronis KN, et al. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011;60(9):1211\u201321.","journal-title":"Metabolism"},{"issue":"9","key":"74_CR24","doi-asserted-by":"crossref","first-page":"E818","DOI":"10.1073\/pnas.1214554110","volume":"110","author":"G Matarese","year":"2013","unstructured":"Matarese G, La Rocca C, Moon H-S, et al. Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci USA. 2013;110(9):E818\u201327.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"74_CR25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.metabol.2012.03.013","volume":"61","author":"RV Sekhar","year":"2012","unstructured":"Sekhar RV, Jahoor F, Iyer D, et al. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012;61(10):1395\u2013403.","journal-title":"Metabolism"},{"key":"74_CR26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00003088-200847110-00006","volume":"47","author":"JL Chan","year":"2008","unstructured":"Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet. 2008;47:753\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"74_CR27","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1210\/jc.2006-2864","volume":"92","author":"JL Chan","year":"2007","unstructured":"Chan JL, Wong SL, Orlova C. Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab. 2007;92:2307\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"74_CR28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.282.16.1517","volume":"282","author":"K Fujioka","year":"1999","unstructured":"Fujioka K, Patane J, Lubina J. CSF leptin levels after exogenous administration of recombinant methionyl human leptin. JAMA. 1999;282:1517\u20138.","journal-title":"JAMA"},{"issue":"12","key":"74_CR29","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.ijo.0801447","volume":"24","author":"B Ahren","year":"2000","unstructured":"Ahren B, Baldwin RM, Havel PJ. Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord. 2000;24(12):1579\u201385.","journal-title":"Int J Obes Relat Metab Disord."},{"key":"74_CR30","unstructured":"Mallard SP, Selby LL, Khoo HM. Pharmacokinetics of recombinant methionyl human leptin in male CD-1 mice. Pharm Res. 1997;14(Suppl.):78\u20139."},{"key":"74_CR31","first-page":"124","volume":"67","author":"SL Wong","year":"2000","unstructured":"Wong SL, Bunkin DA, Young J. Placental transfer of r-metHuLEPTIN following subcutaneous injection (abstract no. PII-37). Clin Pharmacol Ther. 2000;67:124.","journal-title":"Clin Pharmacol Ther."},{"key":"74_CR32","unstructured":"Oral EA, Neidert A, Hakim B, et al. Metabolic effects of metreleptin treatment in familial partial lipodystrophy (FPL). Endocrine Reviews Conference: 94th Annual Meeting and Expo of the Endocrine Society, ENDO. 2012;33(3):MON-246."},{"key":"74_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","volume":"53","author":"AY Chong","year":"2010","unstructured":"Chong AY, Lupsa BC, Cochran EK, et al. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53:27\u201335.","journal-title":"Diabetologia."},{"issue":"4","key":"74_CR34","first-page":"A5482","volume":"154","author":"I Jazet","year":"2013","unstructured":"Jazet I, Jonker J, Wijngaarden M, et al. Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement. Ned Tijdschr Geneeskd. 2013;154(4):A5482.","journal-title":"Ned Tijdschr Geneeskd."},{"key":"74_CR35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","volume":"56","author":"JY Park","year":"2007","unstructured":"Park JY, Javor ED, Cochran EK. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56:508\u201316.","journal-title":"Metabolism"},{"key":"74_CR36","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","volume":"91","author":"JH Lee","year":"2006","unstructured":"Lee JH, Chan JL, Sourlas E. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91:2605\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"74_CR37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.metabol.2010.10.002","volume":"60","author":"F Magkos","year":"2011","unstructured":"Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism. 2011;60(7):1045\u20139.","journal-title":"Metabolism"},{"key":"74_CR38","unstructured":"Brown R, Cochran EK, Miller S, et al. Clinical effects of metreleptin treatment in pediatric patients with lipodystrophy [abstract no. 3490.3]. Pediatric Endocrine Society (PES) Annual Meeting; May 4\u20137; 2013; Washington, DC."},{"key":"74_CR39","unstructured":"O\u2019Neil PM, Rogers RL, Malcolm R et al. Assessment of behavioral and mood changes among obese persons receiving exogenous leptin. Obesity Res (Journal of Obesity). 1999;7 Suppl. 1:92."},{"key":"74_CR40","unstructured":"Greenberg AS, Fulioka K, Heymsfield S, et al. Clinical effects of leptin in obesity. Abstract no. S54-3\u00a081st Annual Meeting Endocrine Society Jun 12 1999."},{"issue":"16","key":"74_CR41","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568\u201375.","journal-title":"JAMA"},{"issue":"2","key":"74_CR42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/EJE-11-0252","volume":"165","author":"GK Shetty","year":"2011","unstructured":"Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165(2):249\u201354.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"74_CR43","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","volume":"17","author":"E Ravussin","year":"2009","unstructured":"Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17(9):1736\u201343.","journal-title":"Obesity"},{"issue":"Suppl. 1","key":"74_CR44","first-page":"64","volume":"16","author":"SR Smith","year":"2008","unstructured":"Smith SR, Blundell J, Ravussin E, et al. Enhanced weight loss following pramlintide\/metreleptin combination treatment in overweight and obese subjects is accompanied by improved control of eating [abstract 64-OR]. Obesity. 2008;16(Suppl. 1):64\u20135.","journal-title":"Obesity"},{"key":"74_CR45","unstructured":"Weyer C, Koda J, Smith S, et al. Enhanced weight loss following pramlintide\/metreleptin combination treatment in obese subjects: clinical evidence for restoration of leptin responsiveness by amylin agonism. Diabetes. 2008;57(Suppl. 1):482 ((plus poster) abstr. 1738-P)."},{"issue":"Suppl. 1","key":"74_CR46","first-page":"359","volume":"49","author":"P Hollander","year":"2000","unstructured":"Hollander P, Lewis GF, Schwartz S. A randomized, double-blinded, placebo-controlled study to determine the effects of subcutaneous (SC) recombinant methionyl human leptin (A-100) on glycemic control in obese subjects with diet-treated type 2 diabetes mellitus (DM). Diabetes. 2000;49(Suppl. 1):359.","journal-title":"Diabetes"},{"issue":"6","key":"74_CR47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","volume":"60","author":"H-S Moon","year":"2011","unstructured":"Moon H-S, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes. 2011;60(6):1647\u201356.","journal-title":"Diabetes."},{"issue":"16","key":"74_CR48","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1073\/pnas.1015674108","volume":"108","author":"SH Chou","year":"2011","unstructured":"Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA. 2011;108(16):6585\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"74_CR49","unstructured":"US National Institutes of Health. Metreleptin clinical trials. 2013. http:\/\/www.clinicaltrials.gov\/ct2\/results?term=metreleptin&Search=Searchhttp:\/\/www.clinicaltrials.gov\/ct2\/results?term=metreleptin&Search=Search . Accessed 6 May 2013."},{"key":"74_CR50","unstructured":"Brown RJ, Lutz K, Cochran E, et al. Metreleptin treatment for metabolic abnormalities associated with lipodystrophy: achieving A1C and triglyceride targets [abstract OR17-1]. ENDO; 2013 Jun 15\u201318, San Francisco."},{"key":"74_CR51","unstructured":"US National Institutes of Health. Effects of metreleptin in type I diabetes mellitus. 2013. http:\/\/clinicaltrials.gov\/show\/NCT01268644 . Accessed 22 May 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0074-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0074-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:31Z","timestamp":1559490091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0074-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}